Rocket Doctor Inc. is the telehealth arm of the parent company Rocket Doctor AI. Rocket Doctor Inc’s co-founder and CEO, Dr. Bill Cherniak recently conducted an interview discussing the company’s Q2 ‘26 progress. You can watch the entire interview here.
Rocket Doctor AI’s (CSE: AIDR) (OTC: AIRDF) most interesting second-quarter number wasn’t revenue. It was 80.
The digital-health company ended the period with 80 U.S. providers on its roster, but only 30 were active during the quarter. Most of the remainder were still moving through the lengthy process of insurance credentialing. That gap could become an important source of growth.
Rocket Doctor’s U.S. patient visits jumped 196% from the first quarter to 3,911, even as its active clinician network expanded from just 19 to 30 providers. Several of those doctors only came online partway through the quarter. If the company can activate more of its existing roster while maintaining current utilization, patient volume has room to rise without Rocket Doctor having to recruit an entirely new workforce.
That makes Rocket Doctor an unusual telehealth story. The company isn’t simply trying to attract more patients to a virtual clinic. Rather, it is building infrastructure that lets independent physicians create and scale practices of their own.
In this section of the interview, Dr. Cherniak discusses the rapid expansion of Rocket Doctor’s U.S. physician roster and the providers working through credentialing.
‘Shopify for Physicians’
Cherniak has described Rocket Doctor as a “Shopify for physicians.” Doctors remain independent while Rocket Doctor provides software, patient access and much of the infrastructure needed to operate a virtual or hybrid practice. Patients see a unified Rocket Doctor marketplace, while the platform can match them with physicians operating behind it. The model is becoming more interesting as Rocket Doctor builds out the other side of the marketplace: Insurance coverage.
The company said its U.S. in-network footprint reached roughly 24 million covered lives across California, New York and Maryland by the second quarter. That is up sharply from around five million covered lives at the beginning of 2026 as Rocket Doctor signed a string of agreements spanning commercial insurance, Medicare Advantage and Medicaid populations.
Covered lives aren’t the same thing as customers. A health-plan agreement merely gives eligible members a pathway to use Rocket Doctor physicians. The company still has to acquire those patients, match them with providers and get paid. This dynamic explains why the physician roster matters.
Rocket Doctor is effectively assembling three sides of a healthcare network: Insurers provide access to patients, doctors provide capacity, and the company’s technology connects the two. Each side becomes more useful as the others grow.
Credentialing Is the Bottleneck, and Part of the Moat
Rocket Doctor’s current physician numbers expose one of the model’s biggest constraints. Signing up a doctor doesn’t make that doctor immediately available to every insured patient. Providers generally need to be credentialed with individual insurers and networks before they can deliver reimbursed care. Rocket Doctor said most of its 80 U.S. providers were still advancing through that process at the end of the quarter.
Management is evaluating ways to accelerate credentialing, according to its Q2 update. But that is a clear execution risk. A roster of 80 physicians matters much less if half of them spend months waiting to become productive. At the same time, the complexity may help explain where Rocket Doctor’s competitive advantage could develop.
Building a video-call interface is no longer difficult. Neither is adding scheduling, messaging or basic electronic-health-record functionality. Replicating relationships with dozens of health plans, credentialing physicians across those networks, managing reimbursement and navigating the rules of Medicare, Medicaid and commercial insurance is considerably harder.
If Rocket Doctor can make that infrastructure largely invisible to physicians, the company becomes more valuable than a telehealth software vendor. It becomes a distribution and reimbursement platform for doctors who want to operate independent practices without rebuilding the administrative machinery of a health system.
There are early signs that the network is beginning to produce volume. U.S. visits nearly tripled quarter over quarter, while the active provider count increased about 58%. That suggests utilization per clinician also improved, although the company has not provided enough detail to establish how evenly visits are distributed across providers.
The next useful metrics for investors would be credentialing time, active providers, visits per provider and revenue per visit. Those numbers would show whether the growing roster is translating into a more productive marketplace.
The Next Step Is Recurring Care
Rocket Doctor is also beginning to move beyond episodic telehealth visits. In June, the company announced its first U.S. value-based primary-care agreement alongside a specialty-services agreement with a California independent physician association. The arrangement gives Rocket Doctor access to more than five million eligible members across nine payers and 65 insurance products. More importantly, physicians can manage assigned primary-care patient panels under a recurring per-member-per-month model.
That could materially change the quality of Rocket Doctor’s revenue. A traditional telehealth visit is transactional. A patient has a problem, books a doctor, and generates a reimbursement event. On the other hand, primary-care panels can create longer-running relationships. A physician may manage the same group of patients over time, generating recurring reimbursement while providing preventive care, chronic-disease management and follow-up.
In this section of the interview, Cherniak discusses value-based care, recurring patient relationships and physicians building practices on the Rocket Doctor platform.
The shift also fits the company’s marketplace strategy. A doctor is more likely to build a durable practice on Rocket Doctor if the platform provides not only software and one-off appointments, but also access to a recurring patient base. For Rocket Doctor, recurring patient panels could improve revenue visibility and physician retention at the same time.
However, the opportunity remains early. The company said the value-based arrangement would initially add hundreds of patients to primary-care provider panels, a small figure compared with the millions of covered lives associated with its payer contracts. That is why investors should resist treating large membership figures as revenue forecasts. The critical task is converting potential access into actual patient relationships.
The Financials Still Have Work to Do
The network story is developing faster than Rocket Doctor’s income statement. Second-quarter revenue was C$734,028, up 43% from a year earlier but roughly flat with C$737,103 in the first quarter. Management said part of the disconnect reflects cash-basis recognition of certain U.S. revenue, creating a lag between the surge in visits and reported sales. Losses also remain substantial. Rocket Doctor reported a second-quarter net loss of C$6.67 million, widening from C$4.64 million in the first quarter, while adjusted EBITDA showed a C$4.12 million loss. Cash stood at just C$950,000 at June 30, although the company has also raised capital through subsequent financings.
Gross margin fell to 65% from 75% in the first quarter as U.S. activity grew. The accounting is worth watching because physician payments are included as direct costs alongside corresponding revenue, meaning expanding U.S. volume may mechanically lower reported gross-margin percentages even when gross profit grows.
Those numbers keep the investment thesis firmly in the execution stage. Rocket Doctor has demonstrated that it can sign payer agreements and recruit physicians. And it is beginning to demonstrate that those agreements can generate substantially more patient visits. Now it has to show that the network can translate into attractive economics.
The most encouraging part is that the next stage of growth may already be sitting in Rocket Doctor’s pipeline. The company doesn’t necessarily need another 50 doctors tomorrow. It needs to activate more of the 80 it already has, put patients in front of them and increasingly turn those encounters into recurring relationships. Rocket Doctor has spent the past year building the network, and the next few quarters should show whether the network can build the business.
For more information, visit the company’s website at https://www.rocketdoctor.ai.
Author’s Disclosure: This article reflects the author’s independent analysis and personal views. The content is provided for informational purposes only and should not be considered financial or investment advice. Readers are encouraged to conduct their own independent research and due diligence before making any investment decisions.